Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer We calculated smudge cell percentages (ratio of ...
Investigators say the findings could lead to new therapeutic targets. New research is shedding light on 1 way chronic lymphocytic leukemia (CLL) cells are able to evade the body’s natural defenses.
Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous ...
The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...
More research is necessary, says an expert, to improve responses to CAR-T cell treatments in patients with chronic lymphocytic leukemia. Some of the earliest trials of CAR-T cell therapy have been in ...
Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells
CAR-T treatments like Novartis’ Kymriah have proven effective in some B-cell-driven cancers, with one notable exception: chronic lymphocytic leukemia (CLL). Now, researchers at the University of ...
Monoclonal B-cell lymphocytosis is when your body produces an elevated number of identical B cells. In some cases, it can develop into chronic lymphocytic leukemia. Monoclonal B-cell lymphocytosis ...
This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results